×
About 29,218 results

ALLMedicine™ Acute Lymphoblastic Leukemia Center

Research & Reviews  8,627 results

Deep thermal profiling for detection of functional proteoform groups.
https://doi.org/10.1038/s41589-023-01284-8
Nature Chemical Biology; Kurzawa N, Leo IR et. al.

Mar 22nd, 2023 - The complexity of the functional proteome extends considerably beyond the coding genome, resulting in millions of proteoforms. Investigation of proteoforms and their functional roles is important to understand cellular physiology and its deregulat...

Prognostic factors of childhood acute lymphoblastic leukemia with TCF3::PBX1 in CCCG-AL...
https://doi.org/10.1002/cncr.34741
Cancer Zhang H, Wan Y et. al.

Mar 22nd, 2023 - Contemporary risk-directed treatment has improved the outcome of patients with acute lymphoblastic leukemia (ALL) and TCF3::PBX1 fusion. In this study, the authors seek to identify prognostic factors that can be used to further improve outcome. Th...

Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acut...
https://doi.org/10.1080/10428194.2023.2189803
Leukemia & Lymphoma; Cassaday RD, Zarling LC et. al.

Mar 21st, 2023 - Treatments for adults with newly-diagnosed acute lymphoblastic leukemia (ALL) may be prohibitively toxic and/or resource-intense. To address this, we performed a phase II study of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide,...

Treatment outcomes in childhood acute lymphoblastic leukemia: 40-year experience from a...
https://doi.org/10.1080/08880018.2023.2188889
Pediatric Hematology and Oncology; Chavananon S, Sripornsawan P et. al.

Mar 21st, 2023 - Studies on the long-term treatment outcomes of childhood acute lymphoblastic leukemia (ALL) in resource-limited countries are scarce. The purpose of this study was to assess the evolution of survival outcomes of pediatric ALL in a tertiary care ce...

DNMT3A low-expression is correlated to poor prognosis in childhood B-ALL and confers re...
https://doi.org/10.1186/s12885-023-10724-6
BMC Cancer; Li W, Liu S et. al.

Mar 20th, 2023 - Little is known about DNMT3A expression and its prognostic significance in childhood B cell acute lymphoblastic leukemia (B-ALL). We determined DNMT3A mRNA expression in 102 children with B-ALL. Correlations with relapse-free survival (RFS) and co...

see more →

Guidelines  6 results

Management of adults and children receiving CAR T-cell therapy: 2021 best practice reco...
https://doi.org/10.1016/j.annonc.2021.12.003
Annals of Oncology : Official Journal of the European Soc... Hayden PJ, Roddie C et. al.

Dec 20th, 2021 - Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle cell lympho...

Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelin...
https://doi.org/10.6004/jnccn.2020.0001
Journal of the National Comprehensive Cancer Network : JN... Brown P, Inaba H et. al.

Jan 8th, 2020 - Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Advancements in technology that enhance our understanding of the biology of the disease, risk-adapted therapy, and enhanced supportive care have contributed to improved su...

NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017.
https://doi.org/10.6004/jnccn.2017.0147
Journal of the National Comprehensive Cancer Network : JN... Brown PA, Shah B et. al.

Sep 7th, 2017 - The prognosis for patients with newly diagnosed acute lymphoblastic leukemia (ALL) has improved with the use of more intensive chemotherapy regimens, tyrosine kinase inhibitors, targeted agents, and allogeneic hematopoietic cell transplantation. H...

Initial Diagnostic Workup of Acute Leukemia: Guideline From the College of American Pat...
https://doi.org/10.5858/arpa.2016-0504-CP
Archives of Pathology & Laboratory Medicine; Arber DA, Borowitz MJ et. al.

Feb 23rd, 2017 - - A complete diagnosis of acute leukemia requires knowledge of clinical information combined with morphologic evaluation, immunophenotyping and karyotype analysis, and often, molecular genetic testing. Although many aspects of the workup for acute...

Acute lymphoblastic leukemia.
https://doi.org/10.6004/jnccn.2012.0089
Journal of the National Comprehensive Cancer Network : JN... Alvarnas JC, Brown PA et. al.

Jul 10th, 2012 - The inaugural NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for acute lymphoblastic leukemia (ALL) were developed as a result of meetings convened by a multi-disciplinary panel of experts in 2011. These NCCN Guidelines provide re...

see more →

Drugs  135 results see all →

Clinicaltrials.gov  984 results

Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
https://clinicaltrials.gov/ct2/show/NCT04606433

Mar 15th, 2023 - Phase Ia: To observe the safety and tolerability of GNC-038 in patients with relapsed or refractory non-Hodgkin lymphoma (R/R NHL)/relapsed or refractory acute lymphoblastic leukemia (R/R ALL), To determine the maximum tolerated dose (MTD) or maxi...

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
https://clinicaltrials.gov/ct2/show/NCT05442515

Mar 10th, 2023 - Background: Despite improvements in therapy, acute lymphoblastic leukemia (ALL) contributes to significant morbidity and mortality for children and young adults with cancer. CD19-CAR and CD22-CAR therapy have proven highly effective in inducing re...

Venetoclax Basket Trial for High Risk Hematologic Malignancies
https://clinicaltrials.gov/ct2/show/NCT05292664

Mar 10th, 2023 - This is an investigator-initiated open-label multi-institutional phase I study of venetoclax combination therapy in both myeloid and lymphoid hematologic malignancies. This study is designed as a basket trial with three separate cohorts. All cohor...

Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
https://clinicaltrials.gov/ct2/show/NCT02553460

Mar 10th, 2023 - Treatment will consist of 4 main phases: Remission Induction, Consolidation, Reinduction, and Maintenance. High risk patients will receive a reintensification phase prior to transplant in first remission. REMISSION INDUCTION: Chemotherapy will be ...

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10- 19) in the Treatment of r/r B-ALL Clinical Research
https://clinicaltrials.gov/ct2/show/NCT05747157

Mar 10th, 2023 - This is a single arm , open-label study. This study is indicated for relapsed and/or refractory CD19+ B-cell Acute Lymphoblastic Leukemia . The selections of dose levels and the number of subjects are based on clinical trials of similar foreign pr...

see more →

News  1,926 results

Shortage of Prostate Cancer Drug; Win for DBT Mammo; Double Lung Transplant
https://www.medpagetoday.com/hematologyoncology/othercancers/103570

Mar 16th, 2023 - Lutetium Lu 177 vipivotide tetraxetan (Pluvicto) is currently in shortage, according to the FDA, leaving some prostate cancer patients with limited options; the drug's manufacturer Novartis said it's working to increase production. Meanwhile, the ...

Jimmy Carter's Melanoma; Post-Op Osimertinib Boosts OS; $83K for Unproven Therapy
https://www.medpagetoday.com/hematologyoncology/skincancer/103467

Mar 9th, 2023 - How the successful use of pembrolizumab (Keytruda) for former President Jimmy Carter's metastatic melanoma put "immunotherapy on the map." (Washington Post) A study of molecular changes observed in the breast tissue of transgender men undergoing a...

Targeted Agents Go Head-to-Head for Newly Diagnosed Ph+ ALL
https://www.medpagetoday.com/hematologyoncology/leukemia/103140

Feb 16th, 2023 - In the first randomized comparison of targeted agents for acute lymphoblastic leukemia (ALL), ponatinib (Iclusig) prevailed over imatinib for untreated Philadelphia chromosome-positive (Ph+) cases. More than twice as many patients treated with pon...

Survival Outcomes in Young ALL Vary by Race/Ethnicity
https://www.medpagetoday.com/hematologyoncology/leukemia/102920

Feb 1st, 2023 - While survival outcomes for children and young adults with acute lymphocytic leukemia (ALL) have improved significantly over the last several decades, substantial differences in outcomes by race and ethnicity continue to persist, a secondary analy...

Immunotherapy drug boosts survival in newly diagnosed ALL
https://www.mdedge.com/hematology-oncology/article/260307/all/immunotherapy-drug-boosts-survival-newly-diagnosed-all
Randy Dotinga

Dec 20th, 2022 - NEW ORLEANS – The immunotherapy drug blinatumomab improves survival as a first-line treatment in certain younger adult patients with B-lineage acute lymphoblastic leukemia, investigators have found. The extremely expensive drug is currently Food a.

see more →

Patient Education  9 results see all →